UK-based startup Vicebio has raised $100m to advance its “next-generation vaccines” for respiratory illnesses, including ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

Vicebio has secured $100mn in Series B funding to further develop its vaccines for multiple respiratory infections.

The series B fundraising will support the clinical development of next-generation multivalent vaccines against respiratory ...

The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...

Vicebio Ltd ("Vicebio"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing led by TCGX with ...

The company said it is “very confident in Arexvy, which has a best-in class profile, including the highest efficacy (94 per ...

The trial investigated the efficacy and safety of a once-daily 10-mg, 20-mg, and 50-mg dose of monlunabant vs. placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome.